The efficacy and safety of combined tiotropium and olodaterol via the Respimat<sup>&reg;</sup> inhaler in patients with COPD: results from the Japanese sub-population of the Tonado<sup>&reg;</sup> studies

201632 citationsJournal Articlegold Open Access

Authors

Masakazu Ichinose · Tohoku University

Hiroyuki Taniguchi · Tosei General Hospital

Ayako Takizawa · Boehringer Ingelheim (Japan)

Lars Grönke · Boehringer Ingelheim (Germany)

Lazaro Loaiza · Boehringer Ingelheim (Germany)

Florian Voß · Boehringer Ingelheim (Germany)

Yihua Zhao

Abstract

Consistent with results from the overall population, T+O 5/5 μg was superior to each monotherapy for lung function and SGRQ in the Japanese sub-population of patients with COPD in Tonado(®).

Topics & Keywords

Chronic Obstructive Pulmonary Disease (COPD) Research Respiratory Support and Mechanisms Asthma and respiratory diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: International Journal of COPD

Volume Volume 11, pp. 2017-2027

DOI: 10.2147/copd.s110389

Field-Weighted Citation Impact: 3.84

Command Palette

The efficacy and safety of combined tiotropium and olodaterol via the Respimat&lt;sup&gt;&amp;reg;&lt;/sup&gt; inhaler in patients with COPD: results from the Japanese sub-population of the Tonado&lt;sup&gt;&amp;reg;&lt;/sup&gt; studies

Authors

Abstract

Topics & Keywords

UN Sustainable Development Goals

Publication Details

The efficacy and safety of combined tiotropium and olodaterol via the Respimat<sup>®</sup> inhaler in patients with COPD: results from the Japanese sub-population of the Tonado<sup>®</sup> studies